Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia

Inflammatory Bowel Diseases

Volumn 16, Issue 7, 2010, Pages 1127-1137

  Švec, Jiří ^a,b   Musílková, Jana ^b   Bryndová, Jana ^b   Jirásek, Tomáš ^a   Mandys, Václav ^a   Kment, Milan ^a   Pácha, Jiří ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Colorectal cancer; Proproliferative and antiapoptotic markers; Ulcerative colitis

Indexed keywords

CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTEGRIN LINKED KINASE; PROTEIN TCF 4; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MOUSE; NEOPLASM; NONHUMAN; ONCOGENE C MYB; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; APOPTOSIS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; FEMALE; GENES, MYB; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE II; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERASE; TRANSCRIPTION FACTORS;

EID: 77953706348     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21178     Document Type: Article

References (43)

1. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol. 2004;287:G7-17.
2. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene. 1999;18:7908-7916. (Pubitemid 30066236)
3. Kim PK, Zamora R, Petrosko P, et al. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol. 2001;1:1421-1441.
4. van der Woude CJ, Kleibeuker JH, Jansen PL, et al. Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract. Apoptosis. 2004;9:123-130.
5. Ambs S, Merriam WG, Bennett WP, et al. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998;58:334-341.
6. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994;107:1183-1188.
7. Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995;55: 3785-3789.
8. Ramsay RG, Thompson MA, Hayman JA, et al. Myb expression is higher in malignant human colonic carcinoma and premalignant adenomatous polyps than in normal mucosa. Cell Growth Differ. 1992;3:723-730.
9. Thompson MA, Rosenthal MA, Ellis SL, et al. c-Myb down-regulation is associated with human colon cell differentiation, apoptosis, and decreased Bcl-2 expression. Cancer Res. 1998;58:5168-5175.
10. Kawasaki H, Altieri DC, Lu CD, et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58:5071-5074.
11. Endo T, Abe S, Seidlar HB, et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother. 2004;53:770-776.
12. Dedhar S, Williams B, Hannigan G. Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol. 1999;9:319-323.
13. Marotta A, Parhar K, Owen D, et al. Characterisation of integrinlinked kinase signalling in sporadic human colon cancer. Br J Cancer. 2003;88:1755-1762.
14. Bravou V, Klironomos G, Papadaki E, et al. ILK over-expression in human colon cancer progression correlates with activation of b-catenin, down-regulation of E-cadherin and activation of the Akt-FKHR pathway. J Pathol. 2006;208:91-99.
15. Barker N, Huls G, Korinek V, et al. Restricted high level expression of Tcf-4 protein in intestinal and mammary gland epithelium. Am J Pathol. 1999;154:29-35. (Pubitemid 29031608)
16. Cui J, Zhou X, Liu Y, et al. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of b-catenin, T-cell factor-4 and glycogen synthase kinase 3-b genes. J Gastroenterol Hepatol. 2003;18:280-287.
17. Engelhardt M, Drullinsky P, Guillem J, et al. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res. 1997;3:1931-1941. (Pubitemid 27505118)
18. Yoshida K, Sugino T, Goodison S, et al. Detection of telomerase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer. 1997;75:548-553. (Pubitemid 27085298)
19. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251-255.
20. Noffsinger AE, Belli JM, Miller MA, et al. A unique basal pattern of p53 expression in ulcerative colitis is associated with mutation in the p53 gene. Histopathology. 2001;39:482-92.
21. Nekvasil M, Zadinová M, Tahotná L, et al. Optimum modality for photodynamic therapy of tumors: gels containing liposomes with hydrophobic photosensitizers. Drug Dev Res. 2007;68:235-252.
22. Chen Y, Zheng B, Robbins DH, et al. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int J Cancer. 2007;120:1511-1517.
23. Silver N, Best S, Jiang J, et al. Selection of housekeeping genes for gene expression studies in human reticulocytes using real-time PCR. BMC Mol Biol. 2006;7:33.
24. Jaiswal M, LaRusso NF, Gores GJ. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis. Am J Physiol. 2001;281:G626-634.
25. Singer II, Kawka DW, Scott S, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology. 1996;111:871-885.
26. Tanaka T, Kohno H, Suzuki R, et al. Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int J Cancer. 2006;118:25-34.
27. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362-366. (Pubitemid 28047080)
28. Agoff SN, Brentnall TA, Crispin DA, et al. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol. 2000;157:737-745.
29. Ramsay RG, Friend A, Vizantios Y, et al. Cyclooxygenase-2, a colorectal cancer nonsteroidal anti-inflammatory drug target, is regulated by c-MYB. Cancer Res. 2000;60:1805-1809.
30. Ramsay RG, Barton AL, Gonda TJ. Targeting c-Myb expression in human disease. Expert Opin Ther Targets. 2003;7:235-348.
31. Funato T, Satou J, Kozawa K, et al. Use of c-myb antisepse oligonucleotides to increase the sensitivity of human colon cancer cells to cisplatin. Oncol Rep. 2001;8:807-810. (Pubitemid 33758127)
32. Gavert N, Ben-Ze'ev A. β-Catenin signaling in biological control and cancer. J Cell Biochem. 2007;102:820-828.
33. Zhang T, Otevrel T, Gao Z, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001;61:8664-8667.
34. Endoh T, Tsuji N, Asanuma K, et al. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res. 2005;305:300-311.
35. Yoshida R, Kiyozuka Y, Ichiyoshi H, et al. Change in telomerase activity during human colorectal carcinogenesis. Anticancer Res. 1999; 19:2167-2172.
36. Ghori A, Usselmann B, Ferryman S, et al. Telomerase expression of malignant epithelial cells correlates with Dukes' stage in colorectal cancer. Colorectal Dis. 2002;4:441-446.
37. Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients. Eur J Gastroenterol Hepatol. 2003;15:75-80.
38. Bachor C, Bachor OA, Boukamp P. Telomerase is active in normal gastrointestinal mucosa and not up-regulated in precancerous lesions. J Cancer Res Clin Oncol. 1999;125:453-460.
39. Kanamaru T, Tanaka K, Kotani J, et al. Telomerase activity and hTERT mRNA in development and progression of adenoma to colorectal cancer. Int J Mol Med. 2002;10:205-210.
40. Usselmann B, Newbold M, Morris AG, et al. Deficiency of colonic telomerase in ulcerative colitis. Am J Gastroenterol. 2001;96:1106-1112.
41. Kleideiter E, Friedrich U, Möhring A, et al. Telomerase activity in chronic inflammatory bowel disease. Dig Dis Sci. 2003;48:2328-2332.
42. Myung SJ, Yang SK, Chang HS, et al. Clinical usefulness of telomerase for the detection of colon cancer in ulcerative colitis patients. J Gastroenterol Hepatol. 2005;20:1578-1583.
43. Troussard AA, Costello P, Yoganathan TN, et al. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene. 2000;19:5444-5452.